drugset / Trial / NCT03809455

Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients

NCT03809455

Phase 2 Withdrawn UNICANCER
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase II, prospective, multicentre, single-blinded, randomised study (when fentanyl citrate is used outside of its marketing authorisation) Patients will be enrolled in an observational cohort when the fentanyl citrate is used according to its marketing authorisation.

Timeline

Start
2020-02-01
Primary completion
2022-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 100 ug Intranasal

Indications

No indication recorded.